Earnings summaries and quarterly performance for Perspective Therapeutics.
Executive leadership at Perspective Therapeutics.
Board of directors at Perspective Therapeutics.
Research analysts who have asked questions during Perspective Therapeutics earnings calls.
Recent press releases and 8-K filings for CATX.
Perspective Therapeutics Provides Updates on Radiopharmaceutical Pipeline and Financial Outlook
CATX
New Projects/Investments
Guidance Update
- Perspective Therapeutics' lead program, VMT-α-NET, for SSTR2 positive tumors, demonstrated a 44% overall response rate (ORR) in GAP-NET patients compared to Lutathera's 13% ORR, with a stronger safety profile. Additional data from higher dose cohorts is expected next year.
- The company is also advancing VMED 01, 02 for metastatic melanoma (targeting MC1R) and a FAP-targeting program for solid tumors, with data from both expected next year.
- Perspective Therapeutics has a cash balance of $172 million on its balance sheet, with a historical quarterly burn of approximately $20 million, extending its cash runway until the end of 2026.
- The company is expanding its manufacturing capabilities with operational sites in Iowa and New Jersey, and new facilities under development in Chicago, Houston, and Los Angeles, alongside a secured strategic thorium stockpile for several years.
Dec 2, 2025, 6:00 PM
Perspective Therapeutics (CATX) Provides Update on Clinical Programs, Financials, and Manufacturing
CATX
New Projects/Investments
Guidance Update
- Perspective Therapeutics (CATX) reported a cash runway extending until the end of 2026, with $172 million on its balance sheet from its last filing and a historical burn rate of approximately $20 million per quarter.
- The company's lead program, VMT-α-NET, for SSTR2 positive neuroendocrine tumors, demonstrated a 44% Overall Response Rate (ORR) in GAP-NETs, compared to Lutathera's 13% ORR, with an "incredibly safe" profile showing no long-term renal toxicity or dysphagia. The company is discussing a registrational trial with the FDA, with the 5 mCi dose considered suitable.
- Perspective Therapeutics is also advancing its VMED 01, 02 program for MC1R-positive metastatic melanoma and a FAP program for solid tumors, with data from both programs expected next year.
- The company has operational manufacturing sites in Iowa and New Jersey, and is developing additional facilities in Chicago, Houston, and L.A. to scale up production and handle various isotopes.
Dec 2, 2025, 6:00 PM
Perspective Therapeutics Discusses Radiopharmaceutical Pipeline and Financial Outlook
CATX
New Projects/Investments
Guidance Update
- Perspective Therapeutics highlighted its VMT-α-NET program, an alpha-emitter radiopharmaceutical for SSTR2 positive neuroendocrine tumors, reporting a 44% overall response rate (ORR) in a like-for-like comparison at ESMO, significantly higher than Lutathera's 13% ORR, with a favorable safety profile.
- The company is developing other radiopharmaceutical programs, including VMED 01, 02 for metastatic melanoma (targeting MC1R) and a FAP program for solid tumors, with data expected next year for both.
- Perspective Therapeutics reported a cash runway extending until the end of 2026, with $172 million on the balance sheet and a historical burn rate of approximately $20 million per quarter.
- The company is expanding its manufacturing capabilities with operational sites in Iowa and New Jersey, and new facilities under development in Chicago, Houston, and Los Angeles, supported by a strategic thorium stockpile.
Dec 2, 2025, 6:00 PM
Perspective Therapeutics, Inc. Announces Q3 2025 Results and Business Highlights
CATX
Earnings
New Projects/Investments
Guidance Update
- Perspective Therapeutics, Inc. reported a net loss of $26.0 million, or $0.35 per basic and diluted share, for the three months ended September 30, 2025.
- As of September 30, 2025, the company held approximately $174 million in cash, cash equivalents, and short-term investments, which is expected to fund current planned clinical milestones and operational investments into late 2026.
- The company provided an update on its [212Pb]VMT-α-NET Phase 1/2a study, noting that eight patients have been enrolled into Cohort 3 (6.0 mCi) within three months of its opening.
Nov 10, 2025, 9:20 PM
Perspective Therapeutics discusses updated VMT-α-NET clinical data at ESMO 2025
CATX
New Projects/Investments
Guidance Update
- Perspective Therapeutics presented updated interim clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2025 (ESMO), reporting an objective response rate (ORR) of 44% in patients where all tumors expressed SSTR2, with a median follow-up of 41 weeks.
- The 5 millicuries dose cohort of the VMT-α-NET program demonstrated a compelling clinical profile with strong anti-tumor activity and a favorable safety profile, including no dose-limiting toxicities, no grade 4 or 5 adverse events, and no treatment-related discontinuations.
- Recruitment has been completed for the 5 millicuries dose cohort and has begun for the 6 millicuries DLT cohort in the VMT-α-NET program.
- The company anticipates providing additional anti-tumor activity data from nearly all cohorts by early 2026, with further longer-term data and results from the 6 millicuries dose cohort expected by mid-2026.
Oct 20, 2025, 12:30 PM
CATX Provides Positive Clinical Update for VMT-α-NET and Financial Outlook
CATX
New Projects/Investments
Guidance Update
- CATX's VMT-α-NET, a targeted alpha-particle therapy for advanced SSTR2+ neuroendocrine tumors (NETs), demonstrated an Objective Response Rate (ORR) of 44% (7 of 16 patients with SSTR2+ tumors) at a median follow-up of 41 weeks in its Phase 1/2 study.
- The treatment was well-tolerated, with no grade 4 or 5 adverse events or treatment-related discontinuations reported among the 55 patients treated as of September 12, 2025.
- This interim data suggests potential for greater efficacy compared to Lutathera (13% ORR) and supports a potential registration study.
- As of September 30, 2025, CATX reported ~$174 million in cash, cash equivalents, and short-term investments, providing sufficient funding into late 2026.
- Upcoming data milestones for VMT-α-NET include anti-tumor activity data from nearly all Cohort 2 patients in early 2026 and initial anti-tumor activity data from the first 8 Cohort 3 patients in mid-2026.
Oct 20, 2025, 12:30 PM
Perspective Therapeutics Reports Encouraging VMT-α-NET Clinical Data
CATX
New Projects/Investments
- Perspective Therapeutics' VMT-α-NET program for neuroendocrine tumors (NETs) shows an encouraging interim readout with an Objective Response Rate (ORR) of 44% for patients meeting NETTER-1 criteria, based on a median follow-up of 41 weeks as of the September 12th data cutoff.
- The VMT-α-NET program has completed recruitment for the second dose cohort at 5 millicuries and has recruited the DLT cohort at 6 millicuries. Additionally, the melanoma program is enrolling at 3 millicuries (monotherapy and combination), and the FAP program is enrolling at 5 millicuries.
- The safety profile of VMT-α-NET is favorable, with no dose-limiting toxicities, no grade 4 or 5 adverse events, no treatment-related discontinuations, and no serious renal complications or dysphagia reported. Creatinine levels in patients have remained quite stable.
- Compared to Lutathera, VMT-α-NET demonstrates a higher frequency of anatomic tumor response and durability with a comparable favorable toxicity profile. The objective response rate would be 47% if AlphaMedix enrollment criteria were applied.
Oct 20, 2025, 12:30 PM
Perspective Therapeutics Reports Positive Interim Clinical Trial Results and Cash Position Update
CATX
New Projects/Investments
Guidance Update
- Perspective Therapeutics, Inc. (CATX) presented updated interim results for its [212Pb]VMT-α-NET Phase 1/2a clinical trial at the ESMO Congress 2025 on October 20, 2025.
- The drug candidate demonstrated continued tolerability and an Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 (patients with SSTR2 expression in all tumors) at a median follow-up of 41 weeks.
- As of September 12, 2025, 14 out of 16 patients in this Cohort 2 group remained free from progression and on study.
- The company's preliminary cash, cash equivalents, and short-term investments totaled approximately $174.1 million as of September 30, 2025, projected to fund operations into late 2026.
Oct 20, 2025, 10:02 AM
Perspective Therapeutics Provides Clinical Program and Financial Update
CATX
New Projects/Investments
Guidance Update
- Perspective Therapeutics is advancing three clinical-stage radiopharmaceutical programs: VMT-01 for melanoma, VMT-a-NET for neuroendocrine tumors, and PSV359 (FAPa targeting) for solid tumors, with multiple readouts expected over the next 12 to 18 months.
- The VMT-a-NET program for neuroendocrine tumors has shown promising results, with eight out of nine patients achieving disease control and one confirmed plus two unconfirmed responses. The Data Safety Monitoring Committee recommended expanding cohort two with up to 40 additional patients.
- The company reported a strong financial position with a cash balance of $227 million as of December 31, 2024, which is projected to fund operations until late 2026.
- Perspective Therapeutics is expanding its manufacturing capabilities, with sites in Iowa and Somerset, New Jersey, currently producing drugs for clinical trials, and plans for additional sites in Los Angeles, Houston, and Chicago.
Mar 3, 2025, 4:10 PM
Quarterly earnings call transcripts for Perspective Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more